GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vaxil Bio VXL.V · CAD

Health Care · TSX Venture · 🇨🇦 Canada

Compare

0.11

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Vaxil Bio — daily TSXV:VXL Delayed
Market value
C$301,354
Last close × shares
Volume
200
Shares, 9 Nov 2026
Price to earnings
0.6

About Vaxil Bio

Its shares trade on TSX Venture under the ticker VXL.V. It has been listed since 2 March 2011.

Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a novel drug discovery and development platform based on signal peptides (SPs) to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, is a MUC1 SP-derived vaccine, which completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The firm has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The firm exploits the unique properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

Figures and description from our data supplier, not checked against the company's own report.

More about Vaxil Bio →

Latest on Vaxil Bio

Our reporting

We have not reported on Vaxil Bio yet.

Next results

26 Nov 2026

Due on 26 Nov 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Vaxil Bio's ticker?

Vaxil Bio trades as VXL.V on TSX Venture, under ISIN CA92243L1076.

What was Vaxil Bio's last closing price?

0.11 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Vaxil Bio next report results?

Results are expected on 26 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.